| Literature DB >> 25930686 |
Kelsey Shields1, Roger V Araujo-Castillo2, Thimmaiah G Theethira3, Carolyn D Alonso4, Ciaran P Kelly5.
Abstract
Clostridium difficile infection (CDI) is increasingly prevalent, dangerous and challenging to prevent and manage. Despite intense national and international attention the incidence of primary and of recurrent CDI (PCDI and RCDI, respectively) have risen rapidly throughout the past decade. Of major concern is the increase in cases of RCDI resulting in substantial morbidity, morality and economic burden. RCDI management remains challenging as there is no uniformly effective therapy, no firm consensus on optimal treatment, and reliable data regarding RCDI-specific treatment options is scant. Novel therapeutic strategies are critically needed to rapidly, accurately, and effectively identify and treat patients with, or at-risk for, RCDI. In this review we consider the factors implicated in the epidemiology, pathogenesis and clinical presentation of RCDI, evaluate current management options for RCDI and explore novel and emerging therapies.Entities:
Keywords: Antibiotic; Fecal microbiota therapy; Infection control; Infectious diarrhea; Nosocomial infection; Toxin
Mesh:
Year: 2015 PMID: 25930686 PMCID: PMC4492812 DOI: 10.1016/j.anaerobe.2015.04.012
Source DB: PubMed Journal: Anaerobe ISSN: 1075-9964 Impact factor: 3.331